Welcome to our dedicated page for Marizyme news (Ticker: MRZM), a resource for investors and traders seeking the latest updates and insights on Marizyme stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marizyme's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marizyme's position in the market.
Marizyme Inc. (OTCQB: MRZM) has appointed Mr. David Barthel as Chief Executive Officer, aiming to advance the company's technology pipeline and drive commercialization efforts for DuraGraft in Europe and Asia while also focusing on FDA submissions for DuraGraft and MATLOC 1 in the U.S. Barthel, who has a strong background in medical device development and leadership, is expected to strengthen the company’s financial position in anticipation of a Nasdaq listing in 2022. His experience includes leading The SmartPill Corp. and Health Logic Interactive Inc.
Marizyme, Inc. (OTCQB: MRZM) has issued a shareholder letter highlighting key updates, including the resignation of CEO Neil Campbell, with Board Chairman James Sapirstein stepping in as interim CEO. The company is expanding its DuraGraft® sales in Europe and pursuing FDA clearance for U.S. commercialization by Q3 2022. DuraGraft is now authorized in 33 countries, supported by eight distributors. Recent developments include new partnerships in Chile and a strengthened executive team, all while aiming for NASDAQ uplisting in 2021.
Marizyme, Inc. (OTCQB:MRZM) has signed a supply and distribution agreement with Abdera Financial, Inc. to distribute its DuraGraft® product in Chile, with potential expansion in South America. This strategic move aims to enhance the market presence and support for DuraGraft, which improves surgical outcomes in coronary artery bypass grafting (CABG) by reducing adverse cardiac events. DuraGraft is already approved in the EU and parts of Asia, but not yet in the U.S. The partnership is expected to strengthen Marizyme’s position in the healthcare market.
Marizyme, Inc. (OTCQB:MRZM) announced the appointment of Julie Kampf as an Independent Member of its Board of Directors. Kampf, a veteran business executive with over 30 years of experience in the life sciences sector, is expected to provide strategic guidance as the company focuses on accelerating clinical and commercial development and enhancing revenue generation. CEO Dr. Neil J. Campbell emphasized her leadership reputation in the industry. Marizyme's flagship product, DuraGraft, aims to improve outcomes in surgical procedures.
Marizyme, Inc. (OTCQB:MRZM), a biotechnology company specializing in ischemia-reperfusion injury solutions, announced key appointments to its senior management team. Roger Schaller was named Executive Vice President of Commercial Operations, while Amy Chandler was promoted to Executive Vice President for Regulatory Affairs and Quality Management Systems. Schaller brings over 30 years of experience in biotech and medical industries, enhancing Marizyme's growth strategy. Chandler's expertise in regulatory affairs will bolster operational efforts. The company's flagship product, DuraGraft, aims to improve outcomes in acute care settings.
Marizyme, Inc. (MRZM) has entered a binding letter of intent with SBH Nutrition Science LLC to develop pet therapeutic products utilizing Marizyme's Krillase® technology. The collaboration aims to create formulations that enhance dental hygiene in pets, targeting a market projected to grow by $1.5 billion by 2022. Marizyme's Krillase technology has demonstrated efficacy in dissolving plaque and biofilms, with results potentially applicable to various mammals. This partnership is expected to expand distribution in Asian, U.S., and European markets.
Marizyme announced at the EACTS Annual Meeting the results of its European DuraGraft Registry, demonstrating positive outcomes for coronary artery bypass grafting (CABG). The clinical registry, involving 3,000 patients across 45 centers, showed low rates of myocardial infarction and revascularization at 30 days and 1 year post-surgery. Dr. Satish Chandran emphasized that DuraGraft enhances surgical outcomes by reducing complications linked to graft failure. DuraGraft is CE-marked and provides crucial ischemic protection, highlighting its potential in improving patient care.
Marizyme, Inc. has successfully completed the acquisition of Somahlution, Inc. and LLC, gaining their DuraGraft intellectual property, crucial for vascular graft protection. As part of the deal, Marizyme issued 10 million shares and raised $7 million in a private placement to support DuraGraft's sales expansion in Europe and initiate FDA approval in the U.S. Notable leadership additions include Dr. Satish Chandra as President and COO. DuraGraft is CE-marked, aimed at reducing complications post-surgery, marking a significant advancement for Marizyme in the acute care market.